Riociguat for the treatment of pulmonary hypertension: Chinese subgroup analyses and comparison

Conclusions Chinese patients displayed differences in baseline characteristics versus the overall populations in PATENT-1 and CHEST-1. Riociguat improved 6MWD, PVR, WHO FC, and other clinical outcomes in Chinese patients with PAH or CTEPH. Trial registration number PATENT-1: NCT00810693, Results; CHEST-1 NCT00855465, Results.

http://heartasia.bmj.com/cgi/content/short/8/1/74?rss=1

Source: Heart Asia - May 16, 2016 Category: Cardiology Authors: Wang, C., Jing, Z.-C., Huang, Y.-G., Zhou, D.-X., Liu, Z.-H., Meier, C., Nikkho, S., Curram, J., Zhang, P., He, J.-G. Tags: Open access Original research Source Type: research